Brand-name drug
Biktarvy price, strengths & recalls
Brand of bictegravir / emtricitabine / tenofovir alafenamide (generic)
Pharmacies pay $4,102.59 for 30 tablets of Biktarvy 50 mg / 200 mg / 25 mg tablet this week, and from $4,098.80 to $4,102.59 across its 2 priced strengths and forms. Its official label last changed on September 14, 2026.
Medicare price 2028Brand- Fair cash price
- $4,728.48
- Strengths
- 2
- Makers
- 1
- Updated
- Nov 11
Biktarvy price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 30 mg / 120 mg / 15 mg tablet Brand | $136.63 | $4,098.80 / 30 tablets |
| 50 mg / 200 mg / 25 mg tablet Brand | $136.75 | $4,102.59 / 30 tablets |
Biktarvy vs generic bictegravir / emtricitabine / tenofovir alafenamide
There is no generic version of Biktarvy on the market yet. Its last listed patent or exclusivity runs to November 8, 2036 - generics often follow, though court cases and settlements can move the date either way.
GenericBictegravir / emtricitabine / tenofovir alafenamide pricesMedicare negotiated price
Biktarvy was selected for Medicare price negotiation. Its negotiated price takes effect on January 1, 2028; the price itself is published by the end of November 2026.
What this means for patients
- The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
- What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
- Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
- If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
Supply status: shortages & recalls
What people paid for Biktarvy
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use BIKTARVY safely and effectively. See full prescribing information for BIKTARVY. BIKTARVY® (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use Initial U.S. Approval: 2018
WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY.
Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients with HIV-1 and HBV who discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1)].
WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning.
Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY. Closely monitor hepatic function in these patients. If appropriate, anti-hepatitis B therapy may be warranted. (5.1)
Recent major changes (as listed on the label)
Indications and Usage (1) | 07/2025 |
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA210251 · Gilead Sciences Inc
- First approved
- February 7, 2018 (8 years ago)
- Latest approved change
- May 21, 2026
- Approved label
- PDF, Aug 17, 2026
- Generic makers
- None on the market
- Last patent listed
- November 8, 2036
- Exclusivity ends
- July 30, 2032
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Biktarvy questions
How much does biktarvy cost without insurance?
Pharmacies pay about $4,102.59 for 30 tablets of biktarvy 50 mg / 200 mg / 25 mg tablet ($136.75 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $4,728.48. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Biktarvy?
Yes: bictegravir / emtricitabine / tenofovir alafenamide. Compare bictegravir / emtricitabine / tenofovir alafenamide prices.
Is biktarvy in shortage?
No shortage is reported for biktarvy right now. We check the national shortage list every day.
Has biktarvy been recalled?
No recalls are on record for biktarvy.
When did the biktarvy label last change?
The official label was last updated on September 14, 2026 (version 26). See what changed.
Does Medicare have a negotiated price for Biktarvy?
Yes - Biktarvy was selected and its negotiated price starts January 1, 2028.
Talk about biktarvy
No comments yet. Questions, tips, what worked for you - start the conversation.